Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus tocilizumab in pediatric active systemic juvenile idiopathic arthritis
CTR20232678Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib, tocilizumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by AbbVie Inc.. Started Apr 2024; status: active.
02
Drugs
upadacitinibtocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on CTR20232678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232678.